Phyllanthus-derived compounds for the prevention and/or treatment of disease associated with a retrovirus

Abstract

The present invention relates to the use a Phyllanthus extract or a fraction thereof or a gallotannin or a combination of gallotannins for the preparation of a pharmaceutical composition for the prevention or treatment of retrovirus related diseases associated with a nucleosidic inhibitor-resistant retrovirus and/or a non-nucleosidic inhibitor-resistant retrovirus. Preferably, the retrovirus is a human immunodeficiency virus (HIV). In accordance with the present invention, it is further preferred that said gallotannin or combination of gallotannins is or comprises corilagin and/or geraniin and another ellagitannin. Further preferred is that said Phyllanthus is Phyllanthus amarus.

1 . Use of a Phyllanthus extract or a fraction thereof or a gallotannin or a combination of gallotannins for the preparation of a pharmaceutical composition for the prevention or treatment of retrovirus-related diseases associated with a nucleosidic inhibitor-resistant retrovirus and/or a non-nucleosidic inhibitor-resistant retrovirus.  
     
     
         2 . Use of a Phyllanthus extract or a fraction thereof or a gallotannin or a combination of gallotannins for the preparation of a pharmaceutical composition for the inhibition of the replication of a nucleosidic inhibitor-resistant retrovirus and/or a non-nucleosidic inhibitor-resistant retrovirus.  
     
     
         3 . Use of a Phyllanthus extract or a fraction thereof or a gallotannin or a combination of gallotannins for the preparation of a pharmaceutical composition for the inhibition of the virus-uptake of a nucleosidic inhibitor-resistant retrovirus and/or a non-nucleosidic inhibitor-resistant retrovirus.  
     
     
         4 . The use of any one of  claims 1  to  3 , wherein said retrovirus is an HIV.  
     
     
         5 . The use of  claim 4 , wherein said HIV is an HIV-1.  
     
     
         6 . The use of any one of  claims 1  to  3 , wherein said extract is a water extract, an alcohol extract, a water/alcohol extract, a hexane extract or a CO 2  extract.  
     
     
         7 . The use of  claim 6 , wherein said alcohol is methanol or ethanol.  
     
     
         8 . The use of any one of  claims 1  to  5 , wherein said fraction is a protein fraction or a gallotannin fraction.  
     
     
         9 . The use of any one of  claims 1  to  5  or  8 , wherein said gallotannin is or said gallotannin fraction comprises corilagin.  
     
     
         10 . The use of any one of claims  1  to or  8 , wherein said gallotannin is or said gallotannin fraction comprises geraniin.  
     
     
         11 . The use of any one of  claims 1  to  5  or  8 , wherein said gallotannin is or said gallotannin fraction comprises ellagic acid.  
     
     
         12 . The use of any one of  claims 1  to  5  or  8 , wherein said gallotannin is or said gallotannin fraction comprises brevifolin carboxylic acid.  
     
     
         13 . The use of any one of  claims 1  to  5  or  8 , wherein said gallotannin is or said gallotannin fraction comprises an ellagitannin different from corilagin, geraniin, ellagic acid and brevifolin carboxylic acid.  
     
     
         14 . The use of  claim 1  to  5  or  8 , wherein said combination of gallotannins or said gallotannin fraction comprises at least two of corilagin, geraniin, ellagic acid and brevifolin carboxylic acid and optionally said ellagitannin different from corilagin and geraniin.  
     
     
         15 . The use of any one of  claims 1  to  14 , wherein said gallotannins are formulated into said pharmaceutical composition in a concentration of 0.1 to 99.9%.  
     
     
         16 . The use of any one of  claims 1  to  15 , wherein said extract or said fraction is present in a concentration of 0.1 to 99.9% in said pharmaceutical composition.  
     
     
         17 . The use of any one of  claims 1  to  16 , wherein said Phyllanthus is Phyllanthus amarus.